Clinuvel flags superior release profile in VLRX-L injectable peptide platform study
I'm LongbridgeAI, I can summarize articles.Clinuvel Pharmaceuticals reported that one of four candidate formulations in its VLRX-L controlled-release liquid injectable peptide platform demonstrated a superior release profile, characterized by lower peak plasma levels and sustained drug presence. The company is now refining the lead formulation at its Singapore R&D center, with manufacturing scale-up underway for melanocortin peptides. A subsequent preclinical study is scheduled for early Q1 2027.
- Clinuvel updated on VLRX-L, a controlled-release liquid injectable peptide platform, following new preclinical data. * One of four candidate formulations showed a stronger release profile, lower peak plasma levels, and drug presence across the target window. * Work now shifts to refining the lead formulation at its Singapore RD&I center, with another preclinical study slated for early Q1 2027. * Manufacturing scale-up is being scoped, with initial platform focus on melanocortin peptides for flexible, individualized dosing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here